Drugs / SOMATROPIN PEGOL
SOMATROPIN PEGOL
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00722540 | Jul 2008 → Apr 2009 | — | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01034202 | Aug 2007 → Jan 2008 | — | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT00936403 | Aug 2009 → Jul 2010 | — | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 2 | NCT00715689 | Jul 2008 → Mar 2009 | pituitary deficiency | Novo Nordisk A/S | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SOMATROPIN PEGOL | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108315 ↗ |
| Known as | NNC126-0083 | “pharmacokinetic and pharmacodynamic response parameters after single and multiple doses of a long-acting rhGH preparation (NNC126-0083).” PMID 20718773 ↗ Dec 2010 |
| Known as | Somatropina pegol | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108315 ↗ |
| Known as | Somatropine pegol | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108315 ↗ |
| Modality | Protein / enzyme biologic | “NNC126-0083 is a pegylated rhGH developed for once-weekly administration.” PMID 21177789 ↗ Dec 2010 |
| Route | Subcutaneous | “NNC126-0083 (0.01, 0.02, 0.04, and 0.08 mg/kg) was given sc once weekly for 3 wk” PMID 21177789 ↗ Dec 2010 |